That doesn’t mean it was simple.

The outlook began brightening for Nvidia last month after AI leaders such as Microsoft, Alphabet and Meta Platforms reaffirmed their plans to invest heavily in AI. That spending has been a boon for Nvidia because its chipsets provide the technology’s brainpower, an advantage that has helped the company’s annual revenue from $27 billion to $130 billion in just two years.Wedbush Securities analyst Dan Ives estimates Big Tech companies will spend about $325 billion on long-term investments primarily revolving around AI this year, with a substantial chunk of that money budgeted for Nvidia’s chips “There is one chip in the world fueling the AI revolution and it’s Nvidia. That narrative is clear from these results,” Ives wrote in a research note.

Trump’s trade war has been raising doubts about Nvidia’s ability to maintain its astounding momentum by threatening to close off other key markets besides China.In apparent attempt to curry favor with the president, Huang last monthsome of its AI chips and supercomputers in plants located in Arizona and Texas. Huang also accompanied

earlier this month, signaling Nvidia’s ambitions to sell more of its AI chips in the Middle East as that region attempts to lessen its economy dependence on oil.Trump also extended a helping hand to Nvidia of by

that had been drawn up under President Joe Biden’s administration that would have broadened the restrictions on chips sales in foreign markets beyond the limits already in place on deals with China and Russia.

“The U.S. will always be Nvidia’s largest market and home to the largest installed base of our infrastructure,” Huang said. “Every nation now sees AI as core to the next industrial revolution.”Even if her new organ fails, doctors can learn from it, Looney told the AP: “You don’t know if it’s going to work or not until you try.”

Pig kidney recipient Towana Looney stands with transplant surgeons Dr. Jayme Locke, left, and Dr. Robert Montgomery, center, at NYU Langone Health. (AP Photo/Shelby Lum)Pig kidney recipient Towana Looney stands with transplant surgeons Dr. Jayme Locke, left, and Dr. Robert Montgomery, center, at NYU Langone Health. (AP Photo/Shelby Lum)

Blacksburg, Virginia-based Revivicor provided Looney’s new kidney from a pig with 10 gene alterations. Its parent company, United Therapeutics said Tuesday it plans to file an application with the FDA “very soon” to begin clinical trials with that type of kidney.Looney was initially discharged on Dec. 6, wearing monitors to track her blood pressure, heart rate and other bodily functions and returning to the hospital for daily checkups before her medication readmission. Doctors scrutinize her bloodwork and other tests, comparing them to prior research in animals and